Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial

医学 肝硬化 意向治疗分析 肝移植 随机对照试验 门脉高压 内科学 人口 外科 经颈静脉肝内门体分流术 胃肠病学 移植 环境卫生
作者
Yong Lv,Zhiping Yang,Lei Liu,Kai Li,Chuangye He,Zhenyu Wang,Wei Bai,Wengang Guo,Tianlei Yu,Xulong Yuan,Hongbo Zhang,Huahong Xie,Liping Yao,Jianhong Wang,Tao Li,Qiuhe Wang,Hui Chen,Enxin Wang,Dongdong Xia,Bohan Luo
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (8): 587-598 被引量:200
标识
DOI:10.1016/s2468-1253(19)30090-1
摘要

Background The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding. Methods We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed. Findings From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25–0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97–100) in the early TIPS group compared with 84% (75–96; absolute risk difference 15% [95% CI 5–48]; p=0·02) and at 1 year was 86% (79–94) in the early TIPS group versus 73% (62–88) in the control group (absolute risk difference 13% [95% CI 2–28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups. Interpretation Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care. Funding National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
海人发布了新的文献求助10
刚刚
努力发芽的小黄豆完成签到 ,获得积分10
1秒前
王三歲完成签到,获得积分10
1秒前
杨荣完成签到,获得积分10
3秒前
111发布了新的文献求助10
3秒前
陈子文完成签到,获得积分10
3秒前
是玥玥啊完成签到,获得积分10
3秒前
酷波er应助豆包采纳,获得10
3秒前
上善若水完成签到 ,获得积分10
3秒前
5秒前
神经网络模型完成签到,获得积分10
5秒前
fan051500完成签到,获得积分10
5秒前
qian完成签到,获得积分20
5秒前
挤你胎霉完成签到,获得积分10
6秒前
xzz完成签到,获得积分10
7秒前
lemon完成签到,获得积分10
8秒前
佳银完成签到,获得积分10
8秒前
金扇扇完成签到 ,获得积分10
8秒前
adamchris完成签到,获得积分10
9秒前
10秒前
慕青应助清爽访曼采纳,获得10
10秒前
10秒前
煎饼果子完成签到 ,获得积分10
10秒前
莫愁一舞完成签到,获得积分10
11秒前
wcli完成签到,获得积分10
11秒前
牛角包完成签到,获得积分10
13秒前
夏天完成签到,获得积分10
13秒前
魔幻凡儿完成签到,获得积分10
15秒前
豆包发布了新的文献求助10
15秒前
白马爱毛驴完成签到,获得积分10
16秒前
17秒前
ji发布了新的文献求助10
17秒前
F123完成签到,获得积分10
18秒前
好运连连完成签到 ,获得积分10
18秒前
新羽完成签到,获得积分10
18秒前
无限的千凝完成签到 ,获得积分10
20秒前
Fxy完成签到 ,获得积分10
20秒前
Bieshiyuan完成签到,获得积分10
20秒前
Zhao完成签到 ,获得积分10
22秒前
23秒前
高分求助中
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
哈工大泛函分析教案课件、“72小时速成泛函分析:从入门到入土.PDF”等 660
Comparing natural with chemical additive production 500
The Leucovorin Guide for Parents: Understanding Autism’s Folate 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
The Social Work Ethics Casebook: Cases and Commentary (revised 2nd ed.) 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5212768
求助须知:如何正确求助?哪些是违规求助? 4388811
关于积分的说明 13664730
捐赠科研通 4249506
什么是DOI,文献DOI怎么找? 2331607
邀请新用户注册赠送积分活动 1329321
关于科研通互助平台的介绍 1282787